RNA Stock Overview
A biopharmaceutical company, engages in the delivery of RNA therapeutics. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Avidity Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$37.93 |
52 Week High | US$56.00 |
52 Week Low | US$6.79 |
Beta | 0.89 |
11 Month Change | -15.37% |
3 Month Change | -6.94% |
1 Year Change | 378.31% |
33 Year Change | 46.56% |
5 Year Change | n/a |
Change since IPO | 33.09% |
Recent News & Updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Recent updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Shareholder Returns
RNA | US Biotechs | US Market | |
---|---|---|---|
7D | -12.5% | -0.8% | 0.4% |
1Y | 378.3% | 12.9% | 32.3% |
Return vs Industry: RNA exceeded the US Biotechs industry which returned 12.9% over the past year.
Return vs Market: RNA exceeded the US Market which returned 32.3% over the past year.
Price Volatility
RNA volatility | |
---|---|
RNA Average Weekly Movement | 9.5% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RNA's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 253 | Sarah Boyce | www.aviditybiosciences.com |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Avidity Biosciences, Inc. Fundamentals Summary
RNA fundamental statistics | |
---|---|
Market cap | US$4.59b |
Earnings (TTM) | -US$280.49m |
Revenue (TTM) | US$10.12m |
447.3x
P/S Ratio-16.1x
P/E RatioIs RNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RNA income statement (TTM) | |
---|---|
Revenue | US$10.12m |
Cost of Revenue | US$260.79m |
Gross Profit | -US$250.67m |
Other Expenses | US$29.82m |
Earnings | -US$280.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.35 |
Gross Margin | -2,477.69% |
Net Profit Margin | -2,772.44% |
Debt/Equity Ratio | 0% |
How did RNA perform over the long term?
See historical performance and comparison